S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
LON:GNS

Genus - GNS Price Target & Analyst Ratings

GBX 2,642
+16.00 (+0.61%)
(As of 08/18/2022 03:37 AM ET)
Add
Compare
Today's Range
2,642
2,658
50-Day Range
2,298
2,838
52-Week Range
2,186
6,310
Volume
62 shs
Average Volume
91,154 shs
Market Capitalization
£1.74 billion
P/E Ratio
4,717.86
Dividend Yield
1.18%
Price Target
GBX 5,120

Genus Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 2 Analyst Ratings

Consensus Analyst Price Target

GBX 5,120
High PredictionGBX 5,740
Average PredictionGBX 5,120
Low PredictionGBX 4,500
TypeCurrent
8/18/21 to 8/18/22
1 Month Ago
7/19/21 to 7/19/22
3 Months Ago
5/20/21 to 5/20/22
1 Year Ago
8/18/20 to 8/18/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetGBX 5,120GBX 5,120GBX 5,348GBX 5,526
Get Genus Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GNS and its competitors with MarketBeat's FREE daily newsletter.


GNS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GNS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Genus Stock vs. The Competition

TypeGenusMedical Companies
Consensus Rating Score
2.50
2.70
Consensus RatingModerate BuyBuy
News Sentiment RatingNeutral News
Positive News
MarketBeat
Community Rating
Outperform Votes
349
70.51%
Underperform Votes
146
29.49%
Avg. Outperform Votes
167
66.80%
Avg. Underperform Votes
83
33.20%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/12/2022Peel Hunt
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHoldGBX 4,500+70.45%
12/7/2021Liberum Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuyGBX 5,740+16.62%
6/29/2021Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHoldGBX 5,500+6.59%
6/29/2021Numis Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingAddGBX 5,500+9.02%
6/22/2021Peel Hunt
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuyGBX 5,500+11.16%
4/1/2020HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuyGBX 3,260 ➝ GBX 3,550+9.16%
11/15/2019Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHoldGBX 3,272+7.14%
(Data available from 8/18/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












GNS Price Target - Frequently Asked Questions

What is Genus's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Genus stock is Moderate Buy based on the current 1 hold rating and 1 buy rating for GNS. The average twelve-month price prediction for Genus is GBX 5,120 with a high price target of GBX 5,740 and a low price target of GBX 4,500. Learn more on GNS's analyst rating history.

Do Wall Street analysts like Genus more than its competitors?

Analysts like Genus less than other Medical companies. The consensus rating for Genus is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how GNS compares to other companies.

Do MarketBeat users like Genus more than its competitors?

MarketBeat users like Genus more than other Medical companies. 70.51% of MarketBeat users gave Genus an outperform vote while medical companies recieve an average of 66.80% outperform votes by MarketBeat users.

Does Genus's stock price have much upside?

According to analysts, Genus's stock has a predicted upside of 35.41% based on their 12-month price targets.


Stock Ratings Reports and Tools

This page (LON:GNS) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.